Fox Run Management L.L.C. Has $527,000 Position in Kiniksa Pharmaceuticals International, plc $KNSA

Fox Run Management L.L.C. lessened its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,563 shares of the company’s stock after selling 22,180 shares during the period. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $527,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Savant Capital LLC bought a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $398,000. GSA Capital Partners LLP raised its holdings in Kiniksa Pharmaceuticals International by 281.9% during the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock worth $3,028,000 after purchasing an additional 57,566 shares during the last quarter. Aberdeen Group plc acquired a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $6,163,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $1,480,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $1,648,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $44.49 on Friday. The company’s 50-day moving average is $42.96 and its 200-day moving average is $39.82. The stock has a market capitalization of $3.37 billion, a PE ratio of 60.12 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 1 year low of $18.25 and a 1 year high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The firm had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm’s quarterly revenue was up 65.0% compared to the same quarter last year. During the same period last year, the company posted ($0.12) earnings per share. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 20,129 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the transaction, the director directly owned 12,546 shares in the company, valued at $520,784.46. This trade represents a 61.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Ragosa sold 42,841 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the sale, the chief financial officer owned 31,086 shares of the company’s stock, valued at $1,289,758.14. This trade represents a 57.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 123,623 shares of company stock valued at $5,236,389 over the last ninety days. 53.48% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on KNSA shares. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price objective for the company. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.